Re: Pfizer/Zenith Trial --- TNBC, non - BRCA -Part 1
in response to
by
...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Message: Trial
Pfizer / Zenith Clinical Trial Collaboration Summary
|
Indication |
2019 |
2020 |
Pfizer Collaboration: Triple Negative Breast Cancer (TNBC, non- BRCA 1/2m)
Phase 1b/2: Combination with PARPi (N~50)
Phase 2/3 TBD
-
Objective: Show safety and activity of ZEN-3694 + talazoparib in TNBC patients, non germline BRCA1/2m
-
Design: Part 1: Dose escalation, Part 2: Simon 2-stage
-
Patient population: TNBC: non-germline BRCA1/2 mutations, locally advanced or metastatic
-
Endpoints: Part 1: Safety, PK/PD, MTD, RP2D; Part 2: Objective response rate (ORR), Duration of response (DOR), rPFS
• ~$400M* peak revenue for ZEN-3694 with significant upside
-
Movement to neo-adjuvant and 1st line TNBC
-
Expansion to other indications combining ZEN-3694 + PARPi in homologous proficient tumors (Ovarian, CRPC,
ER+ breast)
New Message
Please
login
to post a reply